Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPM/oxycodone patch crossover study in post-herpetic neuralgia
ACTRN12615000013561Phase 2Completed
- Sponsor
- Avecho Biotechnology
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxycodone in postherpetic neuralgia (PHN) (2 arms), sponsored by Avecho Biotechnology. Primary endpoint: Change from baseline of average pain intensity by NPRS at 24 and 72 hours. Started Mar 2015; status: completed.
02
Drugs
oxycodone
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on ACTRN12615000013561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000013561.